Elena Bonfiglioli
electroCoreAbout Elena Bonfiglioli
Elena Bonfiglioli, 53, was appointed as an independent, non‑employee Class II director of electroCore, Inc. effective September 2, 2025; her term runs until the 2026 annual meeting following a Board resolution that increased the Board size from seven to eight members . She is Microsoft’s Global Business Leader for Healthcare and Pharma Life Sciences and has held senior health roles in EMEA since 2017; her academic credentials include a Master’s in European Economics (College of Europe), a Laurea in Business/Managerial Economics (University of Modena), and a Licentiate in Applied Economics (University of Montpellier) . The company stated she will receive standard non‑employee director compensation and enter the standard director indemnification agreement; committee assignments were not disclosed at appointment . Her background emphasizes AI/data‑driven transformation and partnerships in global healthcare, with industry recognition as a “Top 50 AI Innovator” by Intelligent Health (twice) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Microsoft | Global Business Leader for Healthcare, Pharma Life Sciences (global go‑to‑market, partnerships, AI transformation) | Jan 2022–present | Leads AI transformation across providers, payors, and life sciences globally . |
| Microsoft (EMEA) | Regional Business Leader for Health & Life Sciences (EMEA) | Aug 2017–present | Senior leadership across commercial strategy in EMEA health . |
| Microsoft (EMEA) | Senior Director – Health Industry (prior roles) | n/d (prior to 2017) | Senior industry leadership in EMEA health . |
| Holomedicine Association | Founding member | n/d | Pioneer in new digital/immersive care models . |
| DIGITALEUROPE Executive Council for Healthcare | Vice Chair | Since 2021 | Policy/industry leadership on digital health in Europe . |
External Roles
| Organization | Role | Since | Notes |
|---|---|---|---|
| DIA (Drug Information Association) – EMEA Regional Advisory Council | Member | 2023 | Advisory role spanning Europe, Middle East & Africa . |
| Women Health Initiative (Kearney) | Board member | 2025 (recent) | Recently joined; women’s health community leadership . |
| Various startups (Europe & Middle East) | Board member | n/d | Board roles across startups (names not disclosed) . |
| Biopharma organizations | Advisor | n/d | Advisor to biopharma/medtech organizations . |
Board Governance
- Appointment and structure: Appointed Class II director effective Sept 2, 2025; Board size increased to eight on that date .
- Leadership: On Sept 2, 2025, Thomas J. Errico, M.D., was appointed Chairman, succeeding retiring Chair F. Peter Cuneo (retirement not due to any disagreement) .
- Committee assignments: No committee assignment for Ms. Bonfiglioli was disclosed at appointment; the 8‑K separately notes a new Audit Committee member (James C. Theofilos) on Aug 1, 2025 .
- Independence: ECOR’s 2025 proxy states all current directors other than the CEO were independent under Nasdaq rules; Ms. Bonfiglioli is a non‑employee director and will receive standard non‑employee director compensation (formal independence designation for her was not explicitly stated at appointment) .
- Attendance and engagement (boardwide context): In 2024, the Board met seven times; all directors attended at least 75% of Board/committee meetings for which they served. Non‑management directors held regular executive sessions led by the (then) independent Chair .
- Governance evolution: The Board is seeking declassification, targeting annual elections for all directors beginning with the 2027 annual meeting, subject to stockholder approval; related charter amendments and removal standards are detailed in the 2025 proxy and Annex A .
Fixed Compensation
| Component | Cash/Value | Notes |
|---|---|---|
| Annual Board retainer (non‑employee director) | $50,000 | Payable quarterly; standard non‑employee director compensation . |
| Non‑executive Chairman retainer | $80,000 | For Chair role (not applicable to Ms. Bonfiglioli) . |
| Audit Committee – Chair | $20,000 | Committee chair cash retainer . |
| Compensation Committee – Chair | $15,000 | Committee chair cash retainer . |
| Nominating & Governance – Chair | $10,000 | Committee chair cash retainer . |
| Audit Committee – Member | $10,000 | Committee member cash retainer . |
| Compensation Committee – Member | $7,500 | Committee member cash retainer . |
| Nominating & Governance – Member | $5,000 | Committee member cash retainer . |
Ms. Bonfiglioli will receive standard non‑employee director compensation; specific committee assignments (and related fees) were not disclosed at appointment .
Performance Compensation
| Equity Component | Value | Vesting | Notes |
|---|---|---|---|
| Initial equity grant (inaugural) | $150,000 | Vests in equal monthly increments over 3 years; accelerates on change of control per plan terms | Granted under 2018 Plan and Director Policy; form may be RSUs/DSUs/options per policy . |
| Annual equity grant (Chair) | $140,000 | 12 equal monthly installments; fully vests on earlier of one‑year anniversary or immediately before next annual meeting; accelerates on CoC | Granted at annual meeting; exercise price for options at or above FMV; 10‑year term for options . |
| Annual equity grant (Other non‑employee directors) | $100,000 | Same as above | Standard annual equity for non‑chair directors . |
The 8‑K confirms she will receive the Company’s standard non‑employee director compensation, including an inaugural equity award under the policy .
Other Directorships & Interlocks
| Company/Organization | Public/Private/Non‑profit | Role | Interlock/Related Party Notes |
|---|---|---|---|
| Various startups (Europe & Middle East) | Private | Board member | Names not disclosed; no ECOR related‑party transactions disclosed . |
| DIA – EMEA Regional Advisory Council | Non‑profit/industry | Member | Advisory role; no ECOR related‑party transactions disclosed . |
| Women Health Initiative (Kearney) | Non‑profit/community | Board member | Recently joined; no ECOR related‑party transactions disclosed . |
| DIGITALEUROPE Exec Council for Healthcare | Industry association | Vice Chair | Policy/industry role; no ECOR related‑party transactions disclosed . |
Expertise & Qualifications
- AI/Data and Healthcare Transformation: Global leadership in AI‑enabled health transformation across providers, payors, and life sciences; recognized twice among “Top 50 AI Innovators” by Intelligent Health .
- Commercial Strategy & Partnerships: Extensive go‑to‑market and partnership experience at Microsoft, including global and EMEA health leadership since 2017 .
- Policy/Industry Engagement: Vice Chair of DIGITALEUROPE’s healthcare council; member of DIA EMEA advisory council; founding Holomedicine Association member .
- Education: College of Europe (Master’s, European Economics); University of Modena (Laurea, Business/Managerial Economics); University of Montpellier (Licentiate, Applied Economics) .
Equity Ownership
- Not yet disclosed in ECOR’s July 10, 2025 beneficial ownership table (pre‑appointment). Ms. Bonfiglioli joined the Board on September 2, 2025 and will receive an inaugural equity award under the non‑employee director policy; specific share counts were not disclosed at appointment .
Governance Assessment
- Board refresh and skills mix: Appointment adds global AI/data health expertise and commercial partnerships capability to ECOR’s Board during a period of governance evolution (declassification targeted by 2027), supporting digital‑health commercialization and strategy oversight .
- Independence and alignment: She is a non‑employee director and will be compensated under the standard policy with a significant equity component (initial $150k and annual $100k for non‑chairs), aligning director incentives with shareholders; no related‑party transactions involving her were disclosed .
- Potential conflicts to monitor (not identified, but risk lens): Given her ongoing senior role at Microsoft, investors should monitor any ECOR‑Microsoft commercial relationships; per ECOR’s Related Party Transaction Policy, the Audit Committee must review/approve any covered related‑person transactions .
- Engagement/attendance outlook: 2024 boardwide attendance met Nasdaq norms (≥75%) and the Board held regular executive sessions; her individual attendance and committee participation will be assessable in the next proxy cycle .
- Process and indemnification: She will enter ECOR’s standard director indemnification agreement; no arrangements/understandings were involved in her selection, signaling a standard refresh process .
Press release confirmation of appointment and context (including quotes) were furnished alongside the 8‑K announcement .